文献速递湿疹皮炎与荨麻疹

靶向IL-13与IL-31RA的单克隆抗体在特应性皮炎中的研发进展

Monoclonal antibodies against interleukin 13 and interleukin 31RA in development for atopic dermatitis.
PubMed 文献 · J Am Acad Dermatol · 2017-12-15

IL-13和IL-31通路是特应性皮炎(AD)的重要病理机制。针对IL-13的两个2期试验均显示湿疹面积和严重度指数(EASI)评分显著下降;针对IL-31受体α的人源化抗体2期试验显示瘙痒、EASI评分及睡眠质量指标呈显著剂量依赖性改善。上述抗体初步显示前景,但长期安全性与有效性数据尚缺乏,未来可能用于中重度AD治疗。

要点

  • 抗IL-13单抗两个2期试验均显示AD患者EASI评分显著下降。
  • 抗IL-31RA抗体2期试验显示瘙痒、EASI及睡眠质量呈剂量依赖性改善。
  • 长期安全性与有效性数据尚缺乏,但可能用于中重度AD。

核心结论

  • 抗IL-13和抗IL-31受体A单克隆抗体的初步临床试验均显示前景,但长期安全性和有效性数据缺乏。
  • 这些药物可能在中重度特应性皮炎治疗中发挥作用。

研究设计与样本

  • 针对IL-13单克隆抗体已有2项2期试验在特应性皮炎治疗中完成。
  • 针对IL-31受体α的人源化抗体有1项2期试验完成。

主要发现

  • 抗IL-13抗体两项2期试验均观察到湿疹面积和严重度指数评分显著降低。
  • 抗IL-31受体α抗体2期试验显示瘙痒、湿疹面积和严重度指数评分及睡眠质量标志物呈显著剂量依赖性降低。

临床怎么用

  • 抗IL-13和抗IL-31受体A单克隆抗体可能用于中重度特应性皮炎的治疗。

局限性

  • 长期安全性和有效性数据缺乏。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The interleukin 13 (IL-13) and IL-31 cytokines and inflammatory pathways have been identified as important for the pathophysiology of atopic dermatitis (AD). Monoclonal antibodies against IL-13 have been studied for the treatment of asthma since 2011. More recently, 2 phase 2 trials have been completed with these antibodies in AD treatment. In both trials, significant reductions of Eczema Area and Severity Index scores were seen. IL-31 is thought to play a role transmitting itch sensation to the central nervous system, and blocking IL-31 activity reduces itch in patients with AD. One phase 2 trial has been completed for a humanized antibody against IL-31 receptor alpha, which is 1 subunit of the IL-31 receptor complex. This study showed significant dose-dependent reductions in pruritus, Eczema Area and Severity Index scores, and markers of sleep quality. Initial clinical trials for monoclonal antibodies against IL-13 and IL-31 receptor A all show promise, although long-term safety and efficacy data are lacking. Nevertheless, these medications will likely play a role in the treatment of moderate-to-severe AD.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Hamann CR, Thyssen JP. Monoclonal antibodies against interleukin 13 and interleukin 31RA in development for atopic dermatitis. J Am Acad Dermatol. 2017. PMID: 29248521. doi:10.1016/j.jaad.2017.12.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。